Topic: The Use of Medical Marijuana for Psychotic Behaviour in Adults
Behaviour issues are rising among persons with intellectual disabilities and mental health problems because they consume psychotropic drugs to manage how their brains function. As I elaborate more on the use of medical marijuana for psychotic behaviours in adults, I will start by saying that psychotic behaviours in adults are a big deal that needs to be dealt with as soon as possible. The behaviours encompass signs like seeing colours and images, hearing sounds, and lots of hallucinations and delusions constitute what needs to be handled. Among the treatment methods for treating psychotic behaviours include medical marijuana. There are special benefits of medical cannabis Sativa utilization to treat hallucinations and delusional behaviour in adults, as discovered in different cases over the years. I will summarize three important articles explaining why medical marijuana is essential for these behaviours. The articles are: The impact of THC and CBD in schizophrenia: A systematic review, Cannabis use among patients with psychotic disorders and Medicinal cannabis for psychiatric disorders: A clinically-focused systematic review.
Ahmed, S., Roth, R. M., Stanciu, C. N., & Brunette, M. F. (2021). The impact of THC and CBD in schizophrenia: A systematic review. Frontiers in Psychiatry, 12. https://doi.org/10.3389/fpsyt.2021.694394
The article focuses on the impact of THC and CBD as contents in cannabis, even for medically consumed amounts. The observation among the sample patients over 30 years aimed to test the response of the psychotic behaviour symptoms after dosage administration. The rationale of the experiment identified how medical cannabis, despite being associated with cannabis use disorder in patients with schizophrenia, bears excellent therapeutic potential. In analyzing the cases drawn for the study and medical marijuana impact, the findings presented positive outcomes for psychosis and cognition. The results explanation identified the ability of the cannabis Sativa contents to offer successful effects among the sample participants matching an advanced improvement in dealing with the symptoms compared to other treatment plans. However, the experiment emphasized controlled trials indicating the necessity to consider the dosage amounts of THC and CBD, which in excess can cause addictive disorders. The content supported the benefit of medical marijuana in brain functions and therapy for psychotic behaviours but with a further research gap to explore the impacts of THC dosage in various drug administration methods to give hope for future cannabis Sativa recommendations.
Hirschtritt, M. E., Young-Wolff, K. C., Mathalon, D. H., & Satre, D. D. (2021). Cannabis use among patients with psychotic disorders. The Permanente Journal, 25(3), 1–5. https://doi.org/10.7812/tpp/20.179
The content introduces interesting research for medical marijuana by allowing the examination of various sides of cannabis consumption among individuals with psychotic disorders. The focus of the study began with a clinically oriented view of cannabis effects on psychosis initial experiences in patients to analyze the changes to positive or negative the situation gets when examining the individuals. With the exploration of the negative side of cannabis consumption in high dosage and regular use, the study provided the positive association of continued use for those experiencing worse psychosis relapses to alter the harms and improvement of behaviours. In explaining the findings, the writers included the motivations of marijuana use for individuals with psychosis, noting the effective moderation the component brings a psychotic management method. The first benefit involved the identification of relief obtained over the negative effect of withdrawal when not trying to support antipsychotic drugs. Also, the context explored social well-being improvement and resolving psychotic issues from medicine dependence on prescribed treatments.
Sarris, J., Sinclair, J., Karamacoska, D., Davidson, M., & Firth, J. (2020). Medicinal cannabis for psychiatric disorders: A clinically-focused systematic review. BMC Psychiatry, 20(1). https://doi.org/10.1186/s12888-019-2409-8
The article’s discussion on cannabis utilization for medical needs opened up with how far other health benefits like pain relief, muscle relaxation, and epilepsy have succeeded, unlike in psychiatry. The study aimed at providing medical marijuana use in psychotic disorders with a recognition of the whole plant contents representations in mental health issues utilization and the possible impacts noted so far. In the experiment, cannabinoid-associated intervention for psychotic disorders was supported by several cases detailing the therapy and mood relaxation effects. Despite the premature medical marijuana use recommendations in psychosis management and symptom reduction, the study developed positive implications in post-traumatic disorder treatment and impacted elimination to patients in psychiatry more than any other treatment plan. Among the aspects to note about the utilization of medical cannabis encompassed the delta-9 tetrahydrocannabinol and cannabidiol limited research in psychotic behaviours handling for preferable use in mania. However, the study through experiment results indicated beneficial outcomes for cannabis administration in schizophrenia social anxiety and sleep improvement for those with post-traumatic experiences. Consequently, medical marijuana benefits in the article were positive, leaving room for proper dosage and administration methods research to offer evidence-based use in future mental health issues.